Full Text
The Full Text of this article is available as a PDF (320.6 KB).
. 1997 Nov;44(5):421–425. doi: 10.1046/j.1365-2125.1997.t01-1-00597.x
Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence—the Australian experience
Suzanne Hill
1, David Henry
1, Brita Pekarsky
2, Andrew Mitchell
3
Suzanne Hill
1
Pharmaceutical Policy Analysis Group, Discipline of Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Newcastle,New South Wales,
Find articles by Suzanne Hill
David Henry
1
Pharmaceutical Policy Analysis Group, Discipline of Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Newcastle,New South Wales,
Find articles by David Henry
Brita Pekarsky
2
Department of General Practice, School of Medicine, The Flinders University of South Australia, South Australia,
Find articles by Brita Pekarsky
Andrew Mitchell
3
Pharmaceutical Evaluation Section, Department of Health and Family Services, Canberra, Australia
Find articles by Andrew Mitchell
1
Pharmaceutical Policy Analysis Group, Discipline of Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Newcastle,New South Wales,
2
Department of General Practice, School of Medicine, The Flinders University of South Australia, South Australia,
3
Pharmaceutical Evaluation Section, Department of Health and Family Services, Canberra, Australia
✉
Correspondence to: Dr. S. Hill Discipline of Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Newcastle, Callaghan, New South Wales 2308, Australia.
PMCID: PMC2042870 PMID: 9384457